Your browser doesn't support javascript.
loading
Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade.
Yam-Puc, Juan Carlos; Hosseini, Zhaleh; Horner, Emily C; Gerber, Pehuén Pereyra; Beristain-Covarrubias, Nonantzin; Hughes, Robert; Lulla, Aleksei; Rust, Maria; Boston, Rebecca; Ali, Magda; Fischer, Katrin; Simmons-Rosello, Edward; O'Reilly, Martin; Robson, Harry; Booth, Lucy H; Kahanawita, Lakmini; Correa-Noguera, Andrea; Favara, David; Ceron-Gutierrez, Lourdes; Keller, Baerbel; Craxton, Andrew; Anderson, Georgina S F; Sun, Xiao-Ming; Elmer, Anne; Saunders, Caroline; Bermperi, Areti; Jose, Sherly; Kingston, Nathalie; Mulroney, Thomas E; Piñon, Lucia P G; Chapman, Michael A; Grigoriadou, Sofia; MacFarlane, Marion; Willis, Anne E; Patil, Kiran R; Spencer, Sarah; Staples, Emily; Warnatz, Klaus; Buckland, Matthew S; Hollfelder, Florian; Hyvönen, Marko; Döffinger, Rainer; Parkinson, Christine; Lear, Sara; Matheson, Nicholas J; Thaventhiran, James E D.
Afiliação
  • Yam-Puc JC; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK. jcy28@cam.ac.uk.
  • Hosseini Z; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Horner EC; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Gerber PP; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, Cambridge, UK.
  • Beristain-Covarrubias N; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Hughes R; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Lulla A; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Rust M; Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Boston R; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Ali M; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Fischer K; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Simmons-Rosello E; Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • O'Reilly M; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Robson H; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Booth LH; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Kahanawita L; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Correa-Noguera A; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Favara D; Department of Oncology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
  • Ceron-Gutierrez L; Department of Oncology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
  • Keller B; Department of Clinical Immunology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
  • Craxton A; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Anderson GSF; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Sun XM; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Elmer A; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Saunders C; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Bermperi A; NIHR Cambridge Clinical Research Facility, Cambridge, UK.
  • Jose S; NIHR Cambridge Clinical Research Facility, Cambridge, UK.
  • Kingston N; NIHR Cambridge Clinical Research Facility, Cambridge, UK.
  • Mulroney TE; NIHR Cambridge Clinical Research Facility, Cambridge, UK.
  • Piñon LPG; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Chapman MA; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • MacFarlane M; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Willis AE; Department of Clinical Immunology, Barts Health, London, UK.
  • Patil KR; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Spencer S; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Staples E; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Warnatz K; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Buckland MS; Medical Research Council Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, UK.
  • Hollfelder F; Department of Clinical Immunology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
  • Hyvönen M; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Döffinger R; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Parkinson C; Department of Immunology, University Hospital Zurich, Zurich, Switzerland.
  • Lear S; Department of Clinical Immunology, Barts Health, London, UK.
  • Matheson NJ; UCL GOSH Institute of Child Health Division of Infection and Immunity, Section of Cellular and Molecular Immunology, London, UK.
  • Thaventhiran JED; Department of Biochemistry, University of Cambridge, Cambridge, UK.
Nat Commun ; 14(1): 3292, 2023 06 27.
Article em En | MEDLINE | ID: mdl-37369658
Age-associated B cells (ABC) accumulate with age and in individuals with different immunological disorders, including cancer patients treated with immune checkpoint blockade and those with inborn errors of immunity. Here, we investigate whether ABCs from different conditions are similar and how they impact the longitudinal level of the COVID-19 vaccine response. Single-cell RNA sequencing indicates that ABCs with distinct aetiologies have common transcriptional profiles and can be categorised according to their expression of immune genes, such as the autoimmune regulator (AIRE). Furthermore, higher baseline ABC frequency correlates with decreased levels of antigen-specific memory B cells and reduced neutralising capacity against SARS-CoV-2. ABCs express high levels of the inhibitory FcγRIIB receptor and are distinctive in their ability to bind immune complexes, which could contribute to diminish vaccine responses either directly, or indirectly via enhanced clearance of immune complexed-antigen. Expansion of ABCs may, therefore, serve as a biomarker identifying individuals at risk of suboptimal responses to vaccination.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunidade Humoral / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunidade Humoral / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article